Back to results
US 2026/0285857 A1Published application
Bicyclic and heterocyclic amide compounds
AssigneesProtego Biopharma, Inc., The Scripps Research Institute
InventorsHank Michael James PETRASSI, Huang QIU, Bo QIN, Richard F. LABAUDINIERE, Steven J. WILKENS, Sebastiaan Melvin Lambert van HOUT, Jeffery W. KELLY, Nicholas Lok YAN
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject with light chain amyloidosis.
Claims27
-71. (canceled)
A compound of Formula (VIII):
- or a pharmaceutically acceptable salt thereof, wherein:
- n is 0 or 1;
- R1 is halogen, cyano, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more halogen, cyano, —OH, —NH2, —NHC(═O)(C1-C6 alkyl), —NHS(═O)2(C1-C6 alkyl), or —C(═O)NH2;
- R2a is C1-C6 alkyl optionally substituted with one or more halogen, cyano, —OH, or —NH2;
- R2b is H or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more halogen;
- R2c is H or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more halogen;
- R2d is H;
- or R2a and R2d together form C1-C6 alkylene optionally substituted with one or more halogen;
- Y is C3-C8 cycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more RYa;
- each RYa independently is oxo, halogen, cyano, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)—H, —C(═O)—OH, —C(═O)—O(C1-C6 alkyl), —C(═O)—NH2, —C(═O)—NH(C1-C6 alkyl), —C(═O)—N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally substituted with one or more RYb;
- each RYb independently is oxo, halogen, cyano, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)—H, —C(═O)—OH, —C(═O)—O(C1-C6 alkyl), —C(═O)—NH2, —C(═O)—NH(C1-C6 alkyl), or —C(═O)—N(C1-C6 alkyl)2;
- ring A is
- where * indicates connectivity to the carbonyl group at triazolopyridine;
- ring B is H, C3-C6 cycloalkyl, 4- to 10-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
- Z is absent, —CH2-, —O—, or —C(═O)—;
- each RTa independently is oxo, halogen, cyano, —OH, —ORTb, —NH2, —NHRTb, —N(RTb)2, —C(═O)—H, —C(═O)—RTb, —C(═O)—OH, —C(═O)—ORTb, —C(═O)—NH2, —C(═O)—NHRTb, —C(═O)—N(RTb)2, —S(═O)2—RTb, —S(═O)(═NH)—RTb, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, or C2-C6 alkynyl;
- each RTb is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, or C2-C6 alkynyl;
- and
- each RTb1 independently is oxo, halogen, cyano, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)—H, —C(═O)—OH, —C(═O)—O(C1-C6 alkyl), —C(═O)—NH2, —C(═O)—NH(C1-C6 alkyl), —C(═O)—N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
- wherein when B is H, Z is absent.
17 more elements
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.